AAPL329.26+2.67 (+0.82%) ▲|ABBV255.55+2.17 (+0.86%) ▲|ABT100.86-0.81 (-0.79%) ▼|ACN141.15-3.59 (-2.48%) ▼|ADBE227.00-7.74 (-3.30%) ▼|AMAT565.50+39.80 (+7.57%) ▲|AMD535.45+31.88 (+6.33%) ▲|AMGN363.86-0.31 (-0.09%) ▼|AMT164.83-2.24 (-1.34%) ▼|AMZN247.42-2.57 (-1.03%) ▼|AVGO386.53+8.37 (+2.21%) ▲|AXP351.58-0.36 (-0.10%) ▼|BA210.55+1.07 (+0.51%) ▲|BAC61.37+0.95 (+1.56%) ▲|BKNG177.31-2.14 (-1.19%) ▼|BLK1,053.64-0.48 (-0.05%) ▼|BMY60.48+0.32 (+0.52%) ▲|BNY158.51+1.58 (+1.01%) ▲|BRK-B490.29-0.96 (-0.20%) ▼|C133.18+4.46 (+3.46%) ▲|CAT891.56+27.26 (+3.15%) ▲|CL90.20-1.74 (-1.89%) ▼|CMCSA23.69-0.10 (-0.40%) ▼|COF206.01-0.77 (-0.37%) ▼|COP116.99+1.31 (+1.13%) ▲|COST928.96-6.84 (-0.73%) ▼|CRM169.96-3.83 (-2.20%) ▼|CSCO111.18+0.48 (+0.43%) ▲|CVS109.45+1.84 (+1.71%) ▲|CVX190.07+0.36 (+0.19%) ▲|DE593.14+7.14 (+1.22%) ▲|DHR174.59-26.53 (-13.19%) ▼|DIS96.53+0.12 (+0.12%) ▲|DUK125.08-0.77 (-0.61%) ▼|EMR139.51+2.93 (+2.15%) ▲|FDX314.61+8.39 (+2.74%) ▲|GD370.74+0.14 (+0.04%) ▲|GE342.27+0.97 (+0.28%) ▲|GEV1,089.99+10.81 (+1.00%) ▲|GILD129.68-3.53 (-2.65%) ▼|GM78.91+3.11 (+4.10%) ▲|GOOG348.66-2.71 (-0.77%) ▼|GOOGL349.28-2.71 (-0.77%) ▼|GS1,080.93+25.90 (+2.45%) ▲|HD331.80-1.24 (-0.37%) ▼|HON231.64+5.46 (+2.41%) ▲|IBM211.01-1.99 (-0.93%) ▼|INTC104.36+7.30 (+7.52%) ▲|INTU289.56-4.26 (-1.45%) ▼|ISRG356.94+3.77 (+1.07%) ▲|JNJ250.61+1.79 (+0.72%) ▲|JPM344.94+6.07 (+1.79%) ▲|KO82.03-0.09 (-0.11%) ▼|LIN505.31-6.74 (-1.32%) ▼|LLY1,162.85+15.95 (+1.39%) ▲|LMT505.53-4.01 (-0.79%) ▼|LOW203.87-0.85 (-0.41%) ▼|LRCX322.12+15.36 (+5.01%) ▲|MA541.38-6.07 (-1.11%) ▼|MCD264.64-3.00 (-1.12%) ▼|MDLZ59.68-0.59 (-0.98%) ▼|MDT82.64-0.65 (-0.78%) ▼|META647.27+1.42 (+0.22%) ▲|MMM172.69+13.58 (+8.54%) ▲|MO73.48-1.18 (-1.58%) ▼|MRK125.55+1.15 (+0.92%) ▲|MS215.95+5.01 (+2.38%) ▲|MSFT397.87-4.43 (-1.10%) ▼|MU969.77+104.31 (+12.05%) ▲|NEE87.81-0.20 (-0.22%) ▼|NFLX66.85-0.75 (-1.11%) ▼|NKE43.26-0.22 (-0.49%) ▼|NOW102.24-2.46 (-2.35%) ▼|NVDA205.70+2.42 (+1.19%) ▲|ORCL125.49+4.11 (+3.38%) ▲|PEP134.61-0.86 (-0.63%) ▼|PFE24.89+0.14 (+0.55%) ▲|PG147.55-1.58 (-1.06%) ▼|PLTR133.37-1.48 (-1.10%) ▼|PM190.51-2.21 (-1.15%) ▼|QCOM174.23+3.91 (+2.30%) ▲|RTX196.40+1.96 (+1.01%) ▲|SBUX104.96+0.15 (+0.14%) ▲|SCHW102.57+0.03 (+0.03%) ▲|SO93.55-0.91 (-0.96%) ▼|SPG227.93-0.27 (-0.12%) ▼|T21.99+0.04 (+0.18%) ▲|TMO518.64-7.60 (-1.44%) ▼|TMUS191.19-4.45 (-2.27%) ▼|TSLA380.96+11.39 (+3.08%) ▲|TXN294.51+10.44 (+3.68%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH433.68+12.13 (+2.88%) ▲|UNP294.85-1.40 (-0.47%) ▼|UPS116.08+2.93 (+2.59%) ▲|USB63.45+0.31 (+0.48%) ▲|V358.32-2.25 (-0.62%) ▼|VZ43.37-0.14 (-0.31%) ▼|WFC87.89+1.56 (+1.80%) ▲|WMT110.29-1.91 (-1.70%) ▼|XOM150.97+2.61 (+1.76%) ▲|AAPL329.26+2.67 (+0.82%) ▲|ABBV255.55+2.17 (+0.86%) ▲|ABT100.86-0.81 (-0.79%) ▼|ACN141.15-3.59 (-2.48%) ▼|ADBE227.00-7.74 (-3.30%) ▼|AMAT565.50+39.80 (+7.57%) ▲|AMD535.45+31.88 (+6.33%) ▲|AMGN363.86-0.31 (-0.09%) ▼|AMT164.83-2.24 (-1.34%) ▼|AMZN247.42-2.57 (-1.03%) ▼|AVGO386.53+8.37 (+2.21%) ▲|AXP351.58-0.36 (-0.10%) ▼|BA210.55+1.07 (+0.51%) ▲|BAC61.37+0.95 (+1.56%) ▲|BKNG177.31-2.14 (-1.19%) ▼|BLK1,053.64-0.48 (-0.05%) ▼|BMY60.48+0.32 (+0.52%) ▲|BNY158.51+1.58 (+1.01%) ▲|BRK-B490.29-0.96 (-0.20%) ▼|C133.18+4.46 (+3.46%) ▲|CAT891.56+27.26 (+3.15%) ▲|CL90.20-1.74 (-1.89%) ▼|CMCSA23.69-0.10 (-0.40%) ▼|COF206.01-0.77 (-0.37%) ▼|COP116.99+1.31 (+1.13%) ▲|COST928.96-6.84 (-0.73%) ▼|CRM169.96-3.83 (-2.20%) ▼|CSCO111.18+0.48 (+0.43%) ▲|CVS109.45+1.84 (+1.71%) ▲|CVX190.07+0.36 (+0.19%) ▲|DE593.14+7.14 (+1.22%) ▲|DHR174.59-26.53 (-13.19%) ▼|DIS96.53+0.12 (+0.12%) ▲|DUK125.08-0.77 (-0.61%) ▼|EMR139.51+2.93 (+2.15%) ▲|FDX314.61+8.39 (+2.74%) ▲|GD370.74+0.14 (+0.04%) ▲|GE342.27+0.97 (+0.28%) ▲|GEV1,089.99+10.81 (+1.00%) ▲|GILD129.68-3.53 (-2.65%) ▼|GM78.91+3.11 (+4.10%) ▲|GOOG348.66-2.71 (-0.77%) ▼|GOOGL349.28-2.71 (-0.77%) ▼|GS1,080.93+25.90 (+2.45%) ▲|HD331.80-1.24 (-0.37%) ▼|HON231.64+5.46 (+2.41%) ▲|IBM211.01-1.99 (-0.93%) ▼|INTC104.36+7.30 (+7.52%) ▲|INTU289.56-4.26 (-1.45%) ▼|ISRG356.94+3.77 (+1.07%) ▲|JNJ250.61+1.79 (+0.72%) ▲|JPM344.94+6.07 (+1.79%) ▲|KO82.03-0.09 (-0.11%) ▼|LIN505.31-6.74 (-1.32%) ▼|LLY1,162.85+15.95 (+1.39%) ▲|LMT505.53-4.01 (-0.79%) ▼|LOW203.87-0.85 (-0.41%) ▼|LRCX322.12+15.36 (+5.01%) ▲|MA541.38-6.07 (-1.11%) ▼|MCD264.64-3.00 (-1.12%) ▼|MDLZ59.68-0.59 (-0.98%) ▼|MDT82.64-0.65 (-0.78%) ▼|META647.27+1.42 (+0.22%) ▲|MMM172.69+13.58 (+8.54%) ▲|MO73.48-1.18 (-1.58%) ▼|MRK125.55+1.15 (+0.92%) ▲|MS215.95+5.01 (+2.38%) ▲|MSFT397.87-4.43 (-1.10%) ▼|MU969.77+104.31 (+12.05%) ▲|NEE87.81-0.20 (-0.22%) ▼|NFLX66.85-0.75 (-1.11%) ▼|NKE43.26-0.22 (-0.49%) ▼|NOW102.24-2.46 (-2.35%) ▼|NVDA205.70+2.42 (+1.19%) ▲|ORCL125.49+4.11 (+3.38%) ▲|PEP134.61-0.86 (-0.63%) ▼|PFE24.89+0.14 (+0.55%) ▲|PG147.55-1.58 (-1.06%) ▼|PLTR133.37-1.48 (-1.10%) ▼|PM190.51-2.21 (-1.15%) ▼|QCOM174.23+3.91 (+2.30%) ▲|RTX196.40+1.96 (+1.01%) ▲|SBUX104.96+0.15 (+0.14%) ▲|SCHW102.57+0.03 (+0.03%) ▲|SO93.55-0.91 (-0.96%) ▼|SPG227.93-0.27 (-0.12%) ▼|T21.99+0.04 (+0.18%) ▲|TMO518.64-7.60 (-1.44%) ▼|TMUS191.19-4.45 (-2.27%) ▼|TSLA380.96+11.39 (+3.08%) ▲|TXN294.51+10.44 (+3.68%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH433.68+12.13 (+2.88%) ▲|UNP294.85-1.40 (-0.47%) ▼|UPS116.08+2.93 (+2.59%) ▲|USB63.45+0.31 (+0.48%) ▲|V358.32-2.25 (-0.62%) ▼|VZ43.37-0.14 (-0.31%) ▼|WFC87.89+1.56 (+1.80%) ▲|WMT110.29-1.91 (-1.70%) ▼|XOM150.97+2.61 (+1.76%) ▲|
24.8 C
New York
Tuesday, July 21, 2026

Tag: tumor cells

newssourceFORcompanyinformationcontent1releasesmarket

Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1

OSLO, Norway, Aug. 5, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced that the U.S....

Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE

SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTumor cells

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers